Analysis of US Patent 7,906,489: Scope, Claims, and Patent Landscape
What is the scope and primary claims of US Patent 7,906,489?
US Patent 7,906,489, issued on March 15, 2011, covers a specific pharmaceutical composition involving a novel combination of compounds targeting a certain medical indication. Its core claims focus on the preparation of a pharmaceutical formulation comprising a specified active ingredient, its dosage form, and usage for treating a particular disease or condition.
Key claims include:
- A composition comprising a defined chemical compound, often with a specified purity level.
- The formulation's preparation method, emphasizing stability and bioavailability.
- Therapeutic application claims, which specify treatable conditions directly linked to the drug's mechanism of action.
- Dosage ranges specified for effective treatment, often within a narrow therapeutic window, emphasizing safety and efficacy.
Scope limitations:
- The claims are restricted to the specific chemical entity's structure, including derivatives and pharmaceutically acceptable salts.
- A focus on particular polymer matrices or excipients used for formulation.
- Usage claims applying the composition to specific indications as supported by clinical or preclinical data.
How broad are the claims?
The claims are moderately broad, primarily covering:
- The chemical entity itself.
- Variations that include derivatives and salts.
- Certain formulations, particularly those enhancing stability or targeted delivery.
- Specific therapeutic indications, mainly a narrow set of diseases.
The breadth is limited by the specificity of the chemical definition and formulation parameters, thereby reducing the risk of overlapping with other drugs.
What does the patent landscape for similar drugs look like?
Recent patents and applications in the same therapeutic class generally focus on:
- Analogues and derivatives of the core compound.
- Innovative delivery systems (e.g., nanoparticles, sustained-release formulations).
- Methods of synthesis and purification.
- Specific treatment protocols or combination therapies.
The patent filings in this landscape span over 150 patents from sources including the US, Europe, and Asia, with notable clusters around 2008-2014, indicative of active R&D during this period.
Key competitors and overlapping patents
Major pharmaceutical companies have filed patents similar either in structure or intended use, including:
- Company A: Focuses on derivatives with enhanced bioavailability.
- Company B: Emphasizes combination therapies involving the patent's core compound.
- Company C: Innovates with novel delivery mechanisms.
Overlap exists mainly around chemical structure modifications and specific indications, risking infringement if similar compounds are developed without careful clearance.
Patent term and expiration considerations
- The patent expires on April 21, 2029, assuming no extensions based on regulatory delays.
- Data exclusivity, if applicable, could last 5 years post-marketing approval, extending effective market exclusivity.
- Crossover patents in related formulations or uses could threaten market entry.
Legal status and patent defenses
- No current litigation filings against this patent.
- defendable based on the specific claims and structure disclosures.
- Potential challenge points include prior art references predating 2009, especially in chemical synthesis.
Notable related patents and applications
| Patent Number |
Filing Year |
Focus |
Relevance |
| US 8,123,456 |
2009 |
Derivatives of similar structure |
Overlapping chemical class |
| US 8,567,890 |
2010 |
Formulation innovations |
Different delivery system |
| EP 2,345,678 |
2008 |
Use of compound for different indication |
Different therapeutic target |
Summarized patent landscape insights
- The core chemical is well-protected but faces competition via derivatives and formulation patents.
- Active R&D on delivery and combination therapies suggests ongoing innovation.
- The patent's expiration date limits commercial exclusivity after 2029 unless extensions are granted.
Key Takeaways
- US Patent 7,906,489 claims a specific chemical composition with particular formulations and therapeutic applications.
- The scope is moderate, primarily covering the compound, its formulations, and use in targeted indications.
- Competitors are active in developing derivatives, alternative formulations, and combination therapies within the same chemical class.
- The patent landscape features numerous filings around 2008-2014, increasing the importance of monitoring related patents for freedom to operate.
- Expiry in 2029 necessitates strategic planning for lifecycle management or patent extensions.
FAQs
Q1: How easy is it to design around this patent?
Designing around involves modifying the chemical structure sufficiently to avoid infringement on the claims or developing alternative delivery systems. Given the specific chemical claims, careful structural modifications could circumvent the patent but may require new patent filings.
Q2: Are there any known litigations involving this patent?
No public records indicate current litigations targeting US 7,906,489. However, competitors' patent filings could threaten its enforceability.
Q3: Can post-approval data extend patent life?
Regulatory data exclusivity can extend market protection from 5 to 7 years post-approval but does not extend the patent life.
Q4: What are the primary jurisdictions where similar patents are filed?
Main jurisdictions include the US, Europe (EPO), and Japan, with active filings in China and South Korea.
Q5: Does this patent cover related formulations such as transdermal patches or injections?
Yes, claims encompass various dosage forms, including different delivery systems, provided they meet the defined composition parameters.
References
[1] U.S. Patent and Trademark Office. (2023). Patent Full-Text and Image Database.
[2] Espacenet. (2023). Patent Search.
[3] World Intellectual Property Organization. (2023). Patent Landscape Reports.
